SciSparc unit NeuroThera pursues FDA orphan drug designation for adult Tourette
NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA orphan drug designation for an adult Tourette Syndrome treatment and has engaged RK Strategies for government and public affairs support.